Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping the brain after stroke may stop pain before it starts

NCT ID NCT07202455

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a gentle electrical brain stimulation technique called tDCS, given alongside standard rehab, can prevent the development of chronic neuropathic pain after a stroke. Sixty adults who recently had a stroke will receive either real or sham tDCS for 10 sessions. Researchers will then check if they develop pain 6 months later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device
What this could lead to
If it works, this could point toward a simple, non-drug way to prevent chronic pain after a stroke.
What could go wrong
This is a small, early-stage study (60 people) testing a prevention approach, so results may not apply widely. The treatment is non-invasive but may not be effective for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Ischemic or hemorrhagic stroke confirmed by MRI or scanner * Lesion(s) in somato-sensory areas (i.e. mainly in: the pons, thalamus, internal capsule, basal ganglia and operculo-insular regions) * Sensory and/or motor deficit requiring rehabilitation * Subacute stage (7 to 45 days post-stroke) * No neurological deficit or chronic neuropathic pain prior to stroke * No neuropathic pain at inclusion * Patient can be followed throughout the study. * Information letter read and understood * Able to give informed consent to participate in research * Affiliation with a social security scheme Exclusion Criteria: * Contraindication to tDCS (epilepsy/history of epilepsy, intracranial ferromagnetic material or implanted stimulator, acute eczema or irritated skin over the stimulation area) * Contraindication to MRI (use of a pacemaker or insulin pump, wearing of a metal prosthesis, intracerebral clip or piercing, claustrophobia) * Cognitive or language difficulties preventing comprehension of instructions and/or correct clinical assessment * Patients participating in another research protocol involving a drug in the 30 days prior to inclusion * Drug or psychoactive substance abuse * Pregnant or breast-feeding women * Patients under guardianship or curatorship, deprived of liberty, safeguard of justice * Major depression * Patients with Parkinson's disease * The presence of pre-existing lesions \>1.5 cm (maximum diameter) in a cerebral area belonging to the anatomically defined sensorimotor system * Alcohol abuse * Severe psychiatric disorders (e.g., schizophrenia) * Any tumor disease with a life expectancy of \<1 year * Increased intracranial pressure * Patients with a medical device containing electronics or conductive materials * Patients on continuous oxygen (system not adapted)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central post-stroke pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Etienne Clémentel

    Enval, 63530, France

  • CHU Clemront-Ferrand

    Clermont-Ferrand, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.